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Abstract
Gene expression profiling has revealed that the gene cod-
ing for cannabinoid receptor 1 (CB1) is highly up-regulated
in rhabdomyosarcoma biopsies bearing the typical chro-
mosomal translocations PAX3/FKHR or PAX7/FKHR. Be-
cause cannabinoid receptor agonists are capable of
reducing proliferation and inducing apoptosis in diverse
cancer cells such as glioma, breast cancer, and melanoma,
we evaluated whether CB1 is a potential drug target in
rhabdomyosarcoma. Our study shows that treatment with
the cannabinoid receptor agonists HU210 and Δ9-tetra-
hydrocannabinol lowers the viability of translocation-
positive rhabdomyosarcoma cells through the induction
of apoptosis. This effect relies on inhibition of AKT signal-
ing and induction of the stress-associated transcription
factor p8 because small interfering RNA–mediated
down-regulation of p8 rescued cell viability upon cannabi-
noid treatment. Finally, treatment of xenografts with
HU210 led to a significant suppression of tumor growth
in vivo. These results support the notion that cannabinoid
receptor agonists could represent a novel targeted ap-
proach for treatment of translocation-positive rhabdomyo-
sarcoma. [Mol Cancer Ther 2009;8(7):1838–45]
Introduction
Rhabdomyosarcoma (RMS) is the most common soft-tissue
sarcoma in children, representing 5% to 8% of all childhood
malignancies (1). It is believed to originate from muscle pre-
cursor cells and histology recognizes two major subtypes:
The embryonal subtype (eRMS) accounts for ∼60% of
RMS cases and has a rather good prognosis (2). The alveolar
subtype (2) is less frequent, more aggressive, usually pre-
sents with metastasis, and is thus associated with rather
poor treatment outcome. Although no consistent genetic al-
terations have been identified thus far in eRMS, ∼80% of
aRMS patients display typical chromosomal translocations
t(2;13)(q35;q14) or t(1;13)(p36;q14) encoding for fusion pro-
teins PAX3/FKHR or PAX7/FKHR, respectively (3). These
chimeric transcription factors are oncogenic and presum-
ably act mainly through their gain in transcriptional activity.
To provide insight into molecular changes elicited by these
transcription factors and to find new potential therapeutic
targets for treatment of aRMS, gene expression analysis
was done in a range of RMS biopsies by several research
groups (4–6). These studies consistently revealed a gene ex-
pression signature of up-regulated genes in translocation-
positive versus translocation-negative samples. Interestingly,
translocation-negative aRMS clustered together with eRMS
samples in these analyses. Hence, at the molecular level,
RMScanbedivided into translocation-positiveRMS (tposRMS)
and translocation-negative RMS (tnegRMS).
The gene expression signature of tposRMS contains a
number of receptor molecules that might be potentially
amenable as drug targets. Among these, receptors such as
c-met have already been validated as therapeutic target
(7). However, one of the top-ranking genes in this signature
is the cannabinoid receptor 1 (CB1). Thus far, no studies
have been undertaken to assess whether CB1 might serve
as a future target for therapeutic intervention in this tumor.
Evidence exists since 1975 that cancer cell growth can be in-
hibited by treatment with cannabinoid receptor agonists, as
first described by Munson et al. in Lewis lung carcinoma
cells (8). Since then, additional cancer cell types such as glio-
blastoma (9), breast carcinoma (10), or melanoma (11) were
reported to be sensitive to the antiproliferative action of can-
nabinoids. In general, the antitumoral actions of diverse
cannabinoid receptor agonists are mediated through the
cannabinoid receptor types CB1 and CB2, as reviewed by
Guzman et al. (12). Notably, not only in vitro cell culture sys-
tems are subject to this treatment response but also in vivo
experiments using either xenografts or syngeneic mouse
models have shown the potential of cannabinoids as anti-
cancer agents, without observing major psychoactive or
immune-suppressive effects (8, 13). Recently, the first clini-
cal study using Δ9-tetrahydrocannabinol (THC) in severe
cases of glioblastoma has been reported (14).
At the molecular level, cannabinoids trigger changes in
various signaling pathways in cancer cells. One of the pri-
mary events after cannabinoid treatment is a sustained
de novo synthesis of the lipid second messenger ceramide,
which in turn is followed by inhibition of AKT signaling
(15). Strikingly, both of these signaling events mark a
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major difference between tumor cells and healthy non-
transformed cells, which undergo AKT activation without
de novo synthesis of ceramide after cannabinoid stimula-
tion (16). In parallel to AKT inhibition, alterations in ex-
tracellular signal-regulated kinase (ERK) signaling have
been reported. However, depending on tumor type, either
inhibition (17) or sustained activation (18) has been ob-
served. Recently, the stress-associated transcription factor
p8 was found to be critically involved in cannabinoid-
induced apoptosis of cancer cells (19) as its down-regulation
could rescue viability of various cancer cells (20, 21). At the
end of the signaling cascade, tumor cells either undergo cell
cycle arrest (22, 23) or apoptosis (9, 24).
To improve the treatment outcome of the aggressive
tposRMS subtype, novel targeted therapies are urgently
needed. Therefore, this study aimed to characterize the ef-
fects of cannabinoids on tposRMS cells in vitro as well as
in vivo. Our results show that the CB1 receptor could repre-




HU210 [(−)-1,1-dimethylheptyl analogue of 11-hydroxy-
Δ8-tetrahydrocannabinol] was purchased from Tocris, 2-
methyl-2′-F-anandamide (Met-F-AEA) from Cayman,
AM251 (analogue of SR141716A) from Sigma-Aldrich, and
THC from The Health Concept. All substances were solved
in DMSO. For in vitro experiments, they were applied at final
DMSO concentrations of maximally 0.05% (v/v). For in vivo
experiments, HU210 was prepared at 0.25% DMSO (v/v)
and diluted in PBS supplemented with 5 mg/mL bovine
serum albumin.
Cell Culture
Rh4 and Rh28 tposRMS cells were kindly provided by P.
Houghton (St Jude Children's Research Hospital, Memphis,
TN, USA). RMS13, RD, and MRC-5 lung fibroblast cells were
obtained from the American Type Culture Collection (LGC
Promochem). All cells were routinely maintained in DMEM
supplemented with 10% FCS. When performing viability or
signaling experiments, cells were plated at a density of
17,000/cm2, allowed to adhere overnight, and transferred
to serum-free medium 6 h before starting drug treatments.
Cell Viability and Apoptosis Detection
Cell viability was evaluated in 96-well plates using
methylthiazolyldiphenyl-tetrazolium bromide from Sigma-
Aldrich. Apoptosis was either analyzed with CaspGLOW
red active caspase-3 staining kit (Biovision), allowing label-
ing of apoptotic cells with a fluorescent caspase-3 substrate
and subsequent detection by fluorescence microscopy. Al-
ternatively, the apoptosis-indicating ratio of cleaved to un-
cleaved poly(ADP-ribose)polymerase (PARP) protein was
determined densitometrically by Western blotting.
Reverse Transcriptase-PCR
RNA was extracted with the RNeasy Mini Kit (Qiagen), in-
cluding a DNase digestion step with RNase-free DNase (Qia-
gen). One microgram of total RNA was reverse transcribed
with randomhexamerprimers using theHighCapacity cDNA
Reverse Transcriptase Kit (Applied Biosystems). PCR was
done with primers for hCB1 (5′-CGTGGGCAGCCTGTTCCT-
CA-3′ and 5′-CATGCGGGCTTGGTCTGG-3′) and for glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH;Microsynth)
using the following parameters: After initial denaturation at
94°C for 5 min, cycles (40×) with 94°C for 30 s, 55°C for 30 s,
and 72°C for 45 s was done, followed by a final extension at
72°C for 5 min.
Quantitative Real-time PCR
Quantitative reverse transcription-PCR (RT-PCR) was
done under universal cycling parameters on an ABI7900HT
instrument using commercially available Mastermix and
target probes for CB1, p8, and GAPDH (all from Applied
Biosystems). Cycle threshold (CT) values were normalized
to GAPDH. Relative expression levels of the target genes
among the different samples were calculated using the
ΔΔCT method.
Gene Silencing
Rh4 cells were transfected with 10 nmol/L small interfer-
ing RNA (siRNA) against human p8 (Qiagen) or scrambled
siRNA (Ambion) using GeneEraser (Stratagene). One day
after siRNA transfection, equal numbers of cells were plated
for subsequent viability experiments. p8 down-regulation
efficiency was verified by means of quantitative RT-PCR.
Western Blot Analysis
For detection of intracellular signaling proteins, whole-
cell extract was produced with a lysis buffer consisting
of 50 mmol/L Tris (pH 7.5), 1% Triton X-100, 1 mmol/L
EGTA, 50 mmol/L NaF, 10 mmol/L sodium β-glycero-
phosphate, 5 mmol/L sodium PPi, 1 mmol/L sodium
orthovanadate, 1% phenylmethylsulfonyl fluoride, 0.1% β-
mercaptoethanol, and protease inhibitor cocktail complete
(Roche) according to standard protocols. Samples were son-
icated and equal amounts of protein were used for Western
blotting with the NuPAGE system (Invitrogen). Antibodies
used for detection included rabbit antibodies raised against
CB1 (1:1,000; Affinity Bioreagents), PARP, phospho-AKT
(Ser473), phospho-AKT (Thr308), AKT-total, phospho-ERK
(Thr202/Tyr204), ERK-total, phospho-GSK (Ser21/9), and
GSK (all 1:1,000; from Cell Signaling Technology). Detection
of actin with a rabbit antibody (1:2,000; Sigma-Aldrich) was
used to control for equal protein loading. As secondary an-
tibody, an anti-rabbit antibody conjugated to horseradish
peroxidase (1:2,000; Pierce) was used. Detection was done
with ECL technology (Amersham).
Confocal Microscopy
Cells on coverslips were fixed with paraformaldehyde
(PFA) and incubated with anti-CB1 antibody (1:500; Affinity
Bioreagents) in PBS/2.5% goat serum for 0.5 hours at 37°C.
For visualization, a secondary anti-rabbit antibody labeled
with Alexa Fluor 594 (1:500; Molecular Probes) was used.
Control immunostainings using the secondary antibody
alone were done in parallel. Confocal fluorescence images
were acquired using Laser Sharp 2000 software (Bio-Rad)
and a Confocal Radiance 2000 coupled to an Axiovert
S100 TV microscope (Carl Zeiss).
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Immunohistochemical Staining
Tumors were fixed, embedded in paraffin, and sectioned
into 2-μm slices. Immunohistochemical stainings for Ki67
(Lab Vision Corporation) and cleaved caspase-3 (Cell Sig-
naling Technology) were done on the Ventana Benchmark
automated staining system (Ventana Medical Systems).
Tumorigenicity Assay
Rh4 cells (7.5 × 106) in 100 μL PBS were injected s.c. into
the flank of NOD/LtSz-scid IL2Rγ null (NOG) mice
(The Jackson Laboratory). When tumors reached a size of
150 mm3, mice were randomly assigned to treatment and
control groups and injected peritumorally for 13 d with
0.2 mg/kg HU210 or vehicle (DMSO) alone. Tumor growth
was monitored daily with external caliper, and the tumor
volume was calculated as (4pi/3)((width + length)/4)3. Ani-
mals were sacrificed 1 d after the last treatment.
Statistical Analysis
Statistical analysis was done with two-tailed t test with
the statistics program SPSS. For analysis of tumor growth,
a longitudinal analysis was done by comparing linear re-
gressions of the two groups.
Results
The CB1 Receptor Is Up-Regulated in Translocation-
Positive RMS
Gene expression profiling of RMS biopsy samples shows
a signature for tposRMS (4) that includes, as one of the top-
ranking genes, CNR1, encoding the CB1 receptor (Fig. 1A).
In contrast, transcript levels of the related CNR2 gene, en-
coding the CB2 receptor, were only slightly above back-
ground. To validate the up-regulation of CB1 in tposRMS
cells on both the RNA and protein levels, we first applied
conventional RT-PCR, which revealed a higher expression
of CB1 mRNA in all tposRMS cells than in control cell lines
MRC-5 (fibroblast) and RD (eRMS; Fig. 1B). Indeed, ex-
pression was >10,000-fold higher than in the controls when
assessed quantitatively. In addition, expression of CB1 is
430-fold higher than expression of CB2 inRh4 cells, whereas
in U87MG glioma and A375 melanoma cells, expression of
CB2 is more prevalent (data not shown). Further, CB1 was
expressed in Rh4 cells also at the protein level as shown by
Western blot (Fig. 1C). Last, confocal microscopy of cultured
Rh4 and RD cells (Fig. 1D) showed higher immunofluores-
cence staining intensities for CB1 in Rh4 cells. Hence, ex-
pression of CB1 is evident both on the mRNA and protein
levels in tposRMS cells, confirming the previous findings
using gene expression profiling.
Cannabinoids Reduce the Viability of tposRMS Cells
In vitro
After validating the expression of CB1 in tposRMS cells,
we next assessed the cell viability after treatment with dif-
ferent cannabinoid receptor agonists. Treatment with the
mixed cannabinoid receptor agonist HU-210 reduced the vi-
ability of two tposRMS cell lines in a dose-dependent man-
ner (Fig. 2A). Similarly, the main active component of
marijuana (THC) as well as the anandamide-related com-
pound Met-F-AEA reduced the viability of Rh4 cells in a
dose-dependent manner but not of the tnegRMS cells (RD)
or control nontransformed fibroblasts (MRC-5), which ex-
press lower levels of the CB1 receptor (Fig. 2C and D). Fi-
nally, pharmacologic blockade of the CB1 receptor
significantly restored cell viability of Rh4 cells from 29.2%
(±2.4SD) to 71.9% (±11.2 SD; Fig. 2B), supporting the notion
that the observed reduction in cell viability was specifically
mediated through the CB1 receptor.
Cannabinoids Induce Apoptosis in tposRMS Cells
To determine whether decreased cell viability in tposRMS
cells after cannabinoid treatment is due to apoptosis, caspase-
3 activation and PARP cleavage were analyzed. First, tposRMS
cells were treated with 1.25 μmol/L HU210 and cell extracts
Figure 1. CB1 expression in tposRMS cells. A, gene expression values
of CB1 are shown in arbitrary units. Samples analyzed by microarray
gene expression profiling were translocation-negative (tnegRMS) versus
translocation-positive (tposRMS) biopsy samples. B, quantitative and
normal RT-PCR with primers for CB1 and for GAPDH were done with
cDNA of cell lines MRC-5 (fibroblast); RD (tnegRMS); and Rh4, Rh28,
and RMS13 (all tposRMS) cells. Quantitative results are indicated in
arbitrary units. C, CB1 protein levels of MRC-5, RD, and Rh4 cells were
determined by Western blotting. D, confocal images of immunofluores-
cence stainings with anti-CB1 antibody (red fluorescence) on RD and
Rh4 cells (scale bar, 100 μm).
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were analyzed by immunoblotting for PARP cleavage at dif-
ferent time points (Fig. 3A). Already 6 hours after start of
treatment, PARP cleavage could be observed and after 24
hours, almost no uncleaved protein was detectable. Treat-
ment of Rh4 and Rh28 cells with increasing HU210 concen-
trations showed a similar increase in PARP cleavage,
whereas pretreatment of Rh4 cells with 0.5 μmol/L of
the CB1-specific antagonist AM251 significantly rescued
cleavage of PARP protein (Fig. 3B). At a concentration of
1.25 μmol/L HU210, for example, the ratio of cleaved to un-
cleaved PARP protein could be rescued from 1.13 (±0.05 SD)
to 0.40 (±0.03 SD; Fig. 3C).
Additionally, caspase-3 activation after 24 hours of
HU210 treatment was measured in Rh4 cells (Fig. 3D). A
concentration-dependent increase of cells positively
stained for active caspase-3 was detected with close to
100% apoptotic cells at 1.25 μmol/L of HU210. In line
with the previous results, we also observed that both THC
(2 and 4 μmol/L) and Met-F-AEA (5 and 10 μmol/L)
treatment induced cleavage of PARP protein after 24 hours
of incubation (Fig. 3E and F). Therefore, treatment of
tposRMS with cannabinoids induces apoptosis in tposRMS
cells.
Cannabinoids Inhibit AKT Signaling
Earlier studies investigating effects of cannabinoids on
cancer cells could show alterations in AKT and ERK signal-
ing upon drug treatment. Based on this, we next studied
AKT and ERK signaling in tposRMS cells after cannabinoid
treatment. Among the tposRMS cell lines, Rh4 cells most ac-
curately reflect the translocation-specific gene expression
signature and therefore this cell line was selected as model
system for further studies. They were incubated with
1.25 μmol/L HU210 for 30 minutes and 2 hours before cell
lysis. A rapid decrease in phospho-AKT at Ser473 was de-
tected, indicating inhibition of AKT activity (Fig. 4A). Un-
der the same experimental conditions, phosphorylation of
ERK was found to increase in tposRMS cells after drug
treatment compared with vehicle-treated cells, at both
Thr202/Tyr204 (Fig. 4A, bottom left). Further phosphorylation
on Thr308 of AKT was also reduced. In addition, the AKT
downstream target GSK3β became significantly depho-
sphorylated (Fig. 4A, right). Notably, also THC (2 and
4 μmol/L) as well as Met-F-AEA (5 and 10 μmol/L) trig-
gered dephosphorylation of AKT at Ser473 (Fig. 4B) with a
slight delay compared with HU210. No difference for ERK
phosphorylation was observed with either of these two
substances (data not shown). In summary, all three can-
nabinoid agonists lead to inhibition of AKT signaling in
tposRMS cells, whereas ERK activation was only seen after
treatment with HU210. These experiments suggest that the
AKT pathway is likely to mediate the action of cannabi-
noids in our tumor model.
Cannabinoids Reduce Viabi l i ty through Up-
Regulation of Transcription Factor p8
p8 is a transcription factor involved in cellular stress re-
sponses following cellular injuries through pathways im-
plicated in growth inhibition (25, 26). Furthermore, p8
mediates apoptosis upon cannabinoid treatment of glioblas-
toma (19), pancreatic cancer (20), and breast cancer (21)
cells. Therefore, we tested involvement of p8 in the antipro-
liferative action of HU210, THC, and Met-F-AEA in our
model. p8 levels were assessed in mRNA isolated 16 hours
after the addition of drugs to Rh4 cells. A clear dose-
dependent increase in p8 transcripts up to 6.5-fold was
observed for all cannabinoids used compared with vehicle-
treated control samples (Fig. 5A).
Figure 2. Cannabinoids re-
duce viability of tposRMS cells.
A , c e l l l i n e s R h 4 , R h 2 8
(tposRMS), RD (tnegRMS), and
MRC-5 (fibroblasts) were incu-
bated with increasing concentra-
t i ons o f HU210 fo r 72 h .
Subsequent viability measure-
ments by means of MTT are
shown (n = 3, ±SE; significance
at 1.25 μmol/L: P < 0.005). B,
viabi l i ty measurements are
shown for Rh4 cells preincubated
with vehicle or with 0.5 μmol/L
AM251 before undergoing sub-
sequent treatment with 1 μmol/L
HU210 for 24 h (n= 3, ±SE, sig-
nificance: P < 0.05). C and D,
dose-dependent viability of Rh4,
RD, and MRC-5 cells after treat-
ment with THC for 24 h or Met-
F-AEA for 48 h was measured
(n = 3, ±SE, significance at
5 μmol/L THC and 10 μmol/L
Met-F-AEA: P < 0.05).
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To validate the requirement of p8 up-regulation for in-
duction of apoptosis, p8 expression was specifically
down-regulated by treatment with siRNA. mRNA levels
after treatment were on average down to 16% (±5.5%
SD) 48 hours after transfection. Upon incubation with
1.25 μmol/L of HU210 for 48 hours, viability of scrambled-
transfected cells was reduced to 37% (±9.4 SE), whereas
cells with lower p8 transcript levels showed a rescue in
viability up to 63% (±8.5 SE; Fig. 5B). This suggests that
an increase in p8 levels after cannabinoid treatment is
an important component of the molecular response. These
experiments indicate that p8 mediates, at least in part,
the reduction in viability observed after cannabinoid
treatment.
HU210 Reduces Tumor Growth of tposRMS
Xenografts
To test whether HU210 might have a therapeutic effect on
tposRMS tumors in vivo, tumor xenografts were generated
by s.c. injection of Rh4 cells into immunodeficient NOG
mice. Tumors were treated peritumorally with HU210 daily
for 13 subsequent days. We observed significantly reduced
tumor growth in HU210-treated compared with vehicle-
treated animals (Fig. 6). Tumors were excised after the last
day of treatment and paraffin-embedded sections were
Figure 3. Cannabinoids in-
duce apoptosis in tposRMS cells.
A, Rh4 cells were treated for 6,
16, 24, and 48 h with either
1.25 μmol/L HU210 or DMSO.
Rh28 and Rh4 cell were incubat-
edwith increasing concentrations
of HU210 for 24 h (bottom). Sub-
sequently, Western blotting was
done with an anti-PARP antibody.
B, after preincubation of Rh4
cells with 0.5 μmol/L of CB1 an-
tagonist AM251, HU210 was
added at concentrations of 1 and
1.25 μmol/L HU210 for 20 h.
Cell lysates were probed with an-
t i-PARP (top ) and anti-actin
(bottom) by immunoblotting. C,
densitometric quantification of
the ratio of cleaved to uncleaved
PARP product (values ± SE, n =
2).D, percentage of cells staining
positively for proapoptotic cas-
pase-3 is shown as evaluated af-
ter 20 h of HU210 treatment of
Rh4 cells (values ± SE, n=3, sig-
nificance P < 0.005). Rh4 cells
were either treated with 2 and
4 μmol/L of THC (E) or 5 and
10 μmol/L of Met-F-AEA (F) for
24 h. Protein extractwas analyzed
for PARP and actin by Western
blotting (here shown a represen-
tative blot).
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either H&E stained or subsequently immunohistochemi-
cally analyzed with antibodies against the proliferation
marker Ki67 and the apoptosis indicator cleaved caspase-3.
H&E-stained sections from HU210-treated animals dis-
played a high number of cell-free patches filled with con-
nective tissue, which are probably remains of previously
apoptotic or necrotic areas. In agreement with this, a moder-
ate increase of apoptotic cells, which was variable across
tumors, was detected in HU210-treated mice compared with
vehicle-treated animals (data not shown). On the other hand,
no difference in the staining pattern for Ki67 was observed
among treatment modalities (data not shown). In conclu-
sion, HU210 is capable of reducing aRMS xenograft growth
through induction of apoptosis in vivo.
Discussion
Evidence from in vitro and in vivo experiments suggests that
cannabinoid receptor agonists can reduce tumor growth
and induce apoptosis in several tumor types, including mel-
anoma, breast and prostate cancer, colon cancer, leukemia,
and glioma. However, to our knowledge, the response to
cannabinoid treatment has not been studied in sarcomas
yet. Here, we investigated the effects of cannabinoid recep-
tor agonists in the sarcoma tposRMS, which we not only
confirmed to express high levels of CB1 mRNA but also
showed expression on the protein level by Western blot
and immunohistochemistry.
In vitro, cannabinoid receptor agonists HU210, THC, and
Met-F-AEA exerted an antiproliferative and proapoptotic
action on tposRMS cells through activation of the CB1 re-
ceptor. The specificity of this effect for CB1 was shown by
two means: First, the cell viability in fibroblasts or tnegRMS
control cell lines, which express only low levels of CB1, is
not affected. Second, the CB1-specific antagonist AM251
was able to significantly reduce apoptosis and partially re-
store cell viability. TposRMS cells were most sensitive to
submicromolar concentrations of HU210, THC, and Met-F-
AEA, and comparable with those observed in other cancer
cells such as pancreatic cancer (20), breast cancer (22), or co-
lon cancer (27) cells.
Key events contributing to cannabinoid-triggered induc-
tion of apoptosis in tposRMS cells are diminished AKT sig-
naling and up-regulation of the transcription factor p8.
Whereas cancer cells such as melanoma (11), colon cancer
(17), and glioma (15) also experience dephosphorylation of
AKT after cannabinoid stimulation, nontransformed CB1-
expressing cells such as neurons react with increased phos-
phorylation of AKT under the same circumstances (16, 28).
The key event responsible for this fundamental difference
is still unknown; however, de novo ceramide synthesis (29)
seems to be important for induction of apoptosis in cancer
Figure 4. Cannabinoid recep-
tor agonists affect AKT and ERK
signaling in tposRMS cells. A,
Rh4 cells were incubated with
1.25 μmol/L HU210 for 30 min,
1 h, and 2 h, and cell lysates
were prepared. Then, Western
blotting was done with antibo-
d ies aga inst phospho-AKT




(Thr308; top right) were probed
on extracts of cells treated for
2 h with 1.25 μmol/L of HU210.
B, phosphorylation status of AKT
at Ser473 was analyzed by West-
ern blotting after treatment of
Rh4 cells with 2 and 4 μmol/L
THC (top) or 5 and 10 μmol/L
Met-F-AEA (bottom) for 24 h.
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cells. Apart from AKT, the transcription factor p8 was re-
cently shown to be up-regulated by cannabinoid receptor
agonists and this event seems to be crucial for their sensi-
tivity (19) because knockdown of this gene could rescue
cell viability in cancer cells such as glioma (19), breast can-
cer (21), or pancreatic cancer (20). As shown here, also in
tposRMS cells is p8 a critical mediator of proapoptotic sig-
naling after cannabinoid treatment because inhibition of its
accumulation by means of RNA interference significantly
rescued cell viability. In contrast, the response of the
ERK pathway is not consistent and seems to be either tu-
mor type specific depending on the type of agonist used.
Therefore, it is less likely to play an important role in our
model.
Thus far, HU210 has been used in animal models to in-
vestigate neurogenesis (30) and multiple sclerosis (31) and
was recently shown to prevent formation of preneoplastic
lesions in mouse colon (32). However, HU210 treatment
of xenograft-bearing mice has not been reported thus
far. Here, we observed significantly reduced tumor
growth in HU210-treated animals without overt psychoac-
tive signs. Growth reduction observed was comparable
with other xenograft models treated with cannabinoids,
such as treatment of pancreatic cancer tumors with THC
or JWH-133 (20). A moderate increase in the number of
apoptotic cells was observed in HU210-treated xenograft
sections; however, we cannot exclude other mechanisms
to additionally account for reduction in tumor growth.
However, analysis of transcript levels of myogenic differ-
entiation markers, such as myosin light chain or troponin
C (33), did not significantly differ between treatment mo-
dalities, ruling out the possibility that cannabinoids in-
duce differentiation in tposRMS cells as observed after
inhibition of PAX3/FKHR function.
In comparison with other drug classes such as the broad-
spectrum kinase inhibitor PKC412 investigated in our labo-
ratory (34), HU210 treatment as single agent seems less
efficient in tumor growth reduction. Nevertheless, poten-
tial use of cannabinoids as therapeutic intervention for
tposRMS should still be pursued, possibly in combination
with conventional chemotherapies, kinase inhibitors, or
other targeted agents. Several reports indicate synergistic
activity of cannabinoid receptor agonists in combination
with well-established antineoplastic substances. THC was
reported to act synergistically with suboptimal doses of
doxorubicin or cisplatin (19), and synergism between
HU210 and 5-fluorouracil was recently reported as well (27).
In summary, our results support and extend the previ-
ously shown antitumor activities of cannabinoid receptor
agonists by showing proapoptotic effects of HU210,
THC, and Met-F-AEA on tposRMS cells in vitro and, for
Figure 6. HU210 reduces tumor growth in vivo. NOG mice were in-
jected with 7.5 × 106 tposRMS (Rh4) cells s.c. into the flank. After reach-
ing a tumor size of 100 to 150 mm3, animals were assigned randomly to
either the vehicle (n = 7) or the HU210 (n = 6) group. Treatment was
given daily by injecting either 0.2 mg/kg HU210 or DMSO in PBS peritu-
morally for 13 d, whereas tumor growth was monitored daily and mice
were sacrificed on the day after the last treatment. A, tumor growth over
time is shown for HU210-treated compared with vehicle-treated animals
(±SE, P < 0.001). B and C, representative sections of tumors from
vehicle- and HU210-treated animals were stained with H&E. Original mag-
nification, 100×.
Figure 5. Induction of proapoptotic p8. A, Rh4 cells were treated with
0.5 and 1 μmol/L of HU210, 2.5 and 3.5 μmol/L of THC (B), or 5 and
10 μmol/L of Met-F-AEA for 16 h. RNA was extracted and analyzed for
p8 transcripts with quantitative RT-PCR (n = 3, ±SE, P < 0.05). Values
were normalized to GAPDH. B, p8 was down-regulated by means of siR-
NA. Top, a representative RT-PCR and quantitative values (in arbitrary
units, normalized to scrambled siRNA transfected control cells). Viability
after HU210 (1.25 μmol/L) treatment was assessed at 48 h with MTT
(n = 3, ±SE, P < 0.05).
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the first time, show that HU210 has tumor growth inhibit-
ing properties in vivo. This could represent one possible
novel treatment strategy that might improve outcome in
this pediatric tumor.
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